Sclerotic and retracted supravenous hyperpigmentation associated with combination chemotherapy for metastatic breast carcinoma [16]

British Journal of Dermatology

Volumn 152, Issue 6, 2005, Pages 1383-1385

  Chen, G Y ^a   Lee, J Y Y ^b   Chen, Wen Chieh ^c  

^a TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOTEMUSTINE; METHOTREXATE; NAVELBINE; NITROSOUREA; PENTOXIFYLLINE; PREDNISONE; VINCRISTINE;

ADULT; ARTERIOSCLEROSIS; BREAST CARCINOMA; CASE REPORT; COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; HYPERPIGMENTATION; LETTER; MASTECTOMY; MELANONYCHIA; NAIL DISEASE; PRIORITY JOURNAL; SCLERODERMA; SEROLOGY; SKIN BIOPSY; SKIN MANIFESTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD VESSELS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; HYPERPIGMENTATION; INFUSIONS, INTRAVENOUS; MIDDLE AGED;

EID: 21644473193     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06633.x     Document Type: Letter

References (12)

1. van Toorn DW, Nortier JW, Rubach M et al. Randomized phase II study of FEC day 1 + 8 and FEC day 1 in patients with advanced breast cancer. Breast Cancer Res Treat 2000; 60:57-62.
2. Riccardi A, Pugliese P, Danova M et al. A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01). Br J Cancer 2001; 85:141-6.
3. Pujol RM, Rocamora V, Lopez-Pousa A et al. Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol 1998; 39:839-42.
4. Lang K, Groeger M, Neumann NJ et al. Supravenous hyperpigmentation, transverse leuconychia and transverse melanonychia after chemotherapy for Hodgkin's disease. J Eur Acad Dermatol Venereol 2002; 16:162-3.
5. Schulte-Huermann P, Zumdick M, Ruzicka T. Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma. Dermatology 1995; 191:65-7.
6. Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 1983; 9:645-63.
7. Werth VP, Schumacher HR Jr, von Feldt JM. Linear hyperpigmentation overlying veins in association with collagen vascular disease. J Am Acad Dermatol 1993; 29:1039-40.
8. el-Malt M, Ceelen W, van den Broecke C et al. Influence of neo-adjuvant chemotherapy with 5-fluorouracil on colonic anastomotic healing: experimental study in rats. Acta Chir Belg 2003; 103:309-14.
9. Yu BD, Eisen AZ. Scleroderma. In: Fitzpatrick's Dermatology in General Medicine (Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds), 6th edn. New York: McGraw-Hill, 2003; 1709-18.
10. Yamamoto T. Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma? Clin Immunol 2002; 102:209-16.
11. Passiu G, Cauli A, Atzeni F et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form. Clin Rheumatol 1999; 18:422-4.
12. Berman B, Duncan MR. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol 1990; 123:339-46.